[Clinical examination of diabetic patients treated with monocomponent insulin manufactured by MP Polfa].
An effect of replacing conventional forms of insulin by the monocomponent insulin manufactured by "Polfa" was studied in the group of 22 diabetics. The patients were followed up for 12 months. An effect of monocomponent insulin on daily requirement of insulin, levels of anti-insulin, monocomponent and pancreatic peptide antibodies, compensation of diabetes mellitus, and lipodystrophy were investigated. New insulin preparation decreased anti-insulin and pancreatic peptide antibodies level and markedly diminished lipodystrophy. However, daily insulin requirement, degree of diabetes mellitus compensation, and anti-proinsulin antibodies level remained unchanged.
Orłowska-Kunikowska
E
E
Horoszek-Maziarz
S
S
Loss-Fisior
R
R
Semetkowska-Jurkiewicz
E
E
Dominiak
K
K
Wójcikowski
C
C
D000328:Adult; D000368:Aged; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007328:Insulin / Q000008:administration & dosage* / Q000276:immunology; D008297:Male; D008875:Middle Aged
D007328:Insulin
Badania kliniczne chorych na cukrzyce leczonych insulina jednoszczytowa MP Polfa.